AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23627803 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with PGC
Number of subjects: 192
Study 23627803 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics
Number of subjects: 192
Study 20497250 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide plus optimized background (OB) regimen
Number of subjects: 155
Study 20497250 — intervention group
Group type: COMPARATOR
Intervention: Optimized background (OB) alone (control group)
Number of subjects: 155
Study 19118992 — intervention group
Group type: EXPERIMENTAL
Intervention: AA+DHA (220mg each/day)
Number of subjects: 86
Study 19118992 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (220mg/day)
Number of subjects: 86
Study 19118992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 17544196 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide‐eugenol (ZOE)
Number of subjects: 270
Study 17544196 — intervention group
Group type: EXPERIMENTAL
Intervention: Apexit
Number of subjects: 270
Study 17544196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 270
Study 15262190 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-rich oil (9 g oil/day for 4 weeks)
Number of subjects: 42
Study 15262190 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich oil (9 g oil/day for 4 weeks)
Number of subjects: 42
Study 15262190 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil, 9 g oil/day for 4 weeks)
Number of subjects: 42
Study 11289288 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.3 percent nifedipine and 1.5 percent lidocaine ointment every 12 hours for two weeks
Number of subjects: 98
Study 11289288 — intervention group
Group type: COMPARATOR
Intervention: Topical 1.5 percent lidocaine ointment
Number of subjects: 98
Study 9879778 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 210 mg/m2 as a 3 hour infusion every three weeks until toxicity or progression
Number of subjects: 123
Study 7586773 — intervention group
Group type: EXPERIMENTAL
Intervention: tiaprofenic acid
Number of subjects: 21
Study 7586773 — intervention group
Group type: EXPERIMENTAL
Intervention: indomethacin
Number of subjects: 21
Study 7586773 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 21
Study 2088520 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session post-partum counselling regarding contraception and reproductive behaviour for HIV positive women
Number of subjects: 0
Study 2088520 — intervention group
Group type: COMPARATOR
Intervention: Comparison group of uninfected women matched for pregnancy outcome
Number of subjects: 0
Study 2088520 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session post-partum counselling for HIV positive women
Number of subjects: 0
Study 6102797 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo or low dosages of antipsychotics (PLD)
Number of subjects: 61
Study 6102797 — intervention group
Group type: COMPARATOR
Intervention: High conventional dosages of antipsychotics (HCD)
Number of subjects: 61
Study 31959220 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality intervention during HSG
Number of subjects: 200
Study 31959220 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus immersive VR intervention
Number of subjects: 200
Study 31959220 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive VR intervention
Number of subjects: 200
Study 30979397 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 5354
Study 30979397 — intervention group
Group type: COMPARATOR
Intervention: Other bDMARDs
Number of subjects: 5354
Study 27011294 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg fish oil supplements daily containing 120 mg DHA and 180 mg EPA
Number of subjects: 150
Study 27011294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 24288076 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified quadrant method for measuring femoral tunnel positions
Number of subjects: 41
Study 23196671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hass avocado (68 g) with hamburger
Number of subjects: 11
Study 23196671 — intervention group
Group type: COMPARATOR
Intervention: Hamburger alone (250 g)
Number of subjects: 11
Study 20522672 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi/ARBs
Number of subjects: 452
Study 20522672 — intervention group
Group type: COMPARATOR
Intervention: Not treated with ACEi/ARBs
Number of subjects: 452
Study 18608632 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time of 3-4 hours/day
Number of subjects: 580
Study 18608632 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time of more than 4 hours/day
Number of subjects: 580
Study 18608632 — intervention group
Group type: COMPARATOR
Intervention: Screen time of less than 2 hours/day
Number of subjects: 580
Study 16434753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal‐epidural (CSE) anesthesia
Number of subjects: 80
Study 16434753 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia alone
Number of subjects: 80
Study 12547847 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (titrated up to 100 mg b.i.d.)
Number of subjects: 81
Study 12547847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 11180022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix 1 mg
Number of subjects: 36
Study 11180022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix 3 mg
Number of subjects: 36
Study 11180022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix 5 mg
Number of subjects: 36
Study 11180022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Number of subjects: 36
Study 1726004 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (4 to 6 mg once daily)
Number of subjects: 362
Study 1726004 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 to 50 mg once daily)
Number of subjects: 362
Study 1726004 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 362
Study 1726004 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 362
Study 6354408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (first-generation cephalosporin)
Number of subjects: 44
Study 6354408 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base and metronidazole (oral)
Number of subjects: 44
Study 31474490 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative teaching by a lymphedema expert
Number of subjects: 119
Study 31474490 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard preoperative surgical discussion and literature)
Number of subjects: 119
Study 30288999 — intervention group
Group type: EXPERIMENTAL
Intervention: automated closed-loop therapy
Number of subjects: 16
Study 30288999 — intervention group
Group type: COMPARATOR
Intervention: sensor-augmented pump therapy
Number of subjects: 16
Study 26908016 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies involving drug discontinuation only (37%)
Number of subjects: 1034
Study 26908016 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies involving drug discontinuation with transfusion of red cell concentrates (38%)
Number of subjects: 1034
Study 26908016 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies involving drug discontinuation with transfusion of plasma (23%)
Number of subjects: 1034
Study 26908016 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies involving coagulation factor concentrates (2%)
Number of subjects: 1034
Study 26908016 — intervention group
Group type: COMPARATOR
Intervention: Warfarin management
Number of subjects: 1034
Study 26908016 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-traumatic bleeding management
Number of subjects: 1034
Study 26908016 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic bleeding management
Number of subjects: 1034
Study 26908016 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day mortality rates
Number of subjects: 1034
Study 24650828 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 24650828 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 24650828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22885247 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg THC
Number of subjects: 12
Study 22885247 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg THC
Number of subjects: 12
Study 22885247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22885247 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (all doses)
Number of subjects: 12
Study 19897312 — intervention group
Group type: EXPERIMENTAL
Intervention: BI+Usual Care
Number of subjects: 44
Study 19897312 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 44
Study 17654228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (mean 10 degrees C, s = 0.5) for 10 minutes
Number of subjects: 20
Study 17654228 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-immersion)
Number of subjects: 20
Study 15773823 — intervention group
Group type: COMPARATOR
Intervention: Nociceptin levels in headache-free migraineurs
Number of subjects: 18
Study 15773823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociceptin levels in controls
Number of subjects: 18
Study 15773823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociceptin levels in patients during typical migraine attacks
Number of subjects: 18
Study 15773823 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of nociceptin levels with frequency of attacks in migraineurs
Number of subjects: 18
Study 11812708 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic sport drinks
Number of subjects: 60
Study 11812708 — intervention group
Group type: COMPARATOR
Intervention: Water only
Number of subjects: 60
Study 10363564 — intervention group
Group type: EXPERIMENTAL
Intervention: Mn-SOD in carcinomas and liver metastases
Number of subjects: 105
Study 10363564 — intervention group
Group type: EXPERIMENTAL
Intervention: Mn-SOD in adenomas
Number of subjects: 105
Study 10363564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu/Zn-SOD in liver metastases
Number of subjects: 105
Study 10363564 — intervention group
Group type: COMPARATOR
Intervention: Cu/Zn-SOD in adenomas, carcinomas, and normal mucosa
Number of subjects: 105
Study 7739942 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic slow-release theophylline tablet
Number of subjects: 14
Study 7739942 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur
Number of subjects: 14
Study 2154070 — intervention group
Group type: EXPERIMENTAL
Intervention: VLCD with dietary fibre
Number of subjects: 22
Study 2154070 — intervention group
Group type: COMPARATOR
Intervention: VLCD without dietary fibre
Number of subjects: 22
Study 6342643 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 micrograms
Number of subjects: 12
Study 6342643 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (various doses)
Number of subjects: 12
Study 6342643 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 12
Study 30586756 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 118
Study 30586756 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 118
Study 29356928 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐directed, technology‐based sessions
Number of subjects: 412
Study 29356928 — intervention group
Group type: COMPARATOR
Intervention: in‐person, small group sessions led by facilitators
Number of subjects: 412
Study 29356928 — intervention group
Group type: COMPARATOR
Intervention: literature control with home‐mailed educational materials
Number of subjects: 412
Study 27098817 — intervention group
Group type: EXPERIMENTAL
Intervention: CET as a smartphone application
Number of subjects: 300
Study 27098817 — intervention group
Group type: EXPERIMENTAL
Intervention: CET as group therapy
Number of subjects: 300
Study 27098817 — intervention group
Group type: COMPARATOR
Intervention: Aftercare as Usual
Number of subjects: 300
Study 24677247 — intervention group
Group type: EXPERIMENTAL
Intervention: Late onset melancholic depression (LOD-M)
Number of subjects: 284
Study 24677247 — intervention group
Group type: EXPERIMENTAL
Intervention: Early onset melancholic depression (EOD-M)
Number of subjects: 284
Study 24677247 — intervention group
Group type: COMPARATOR
Intervention: Age at onset (predictor)
Number of subjects: 284
Study 23054852 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 80
Study 20386062 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative arts therapy (CAT)
Number of subjects: 16
Study 20386062 — intervention group
Group type: COMPARATOR
Intervention: Volunteer attention (Control)
Number of subjects: 16
Study 18714203 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (body stroking and passive limb movements for three, 15-minute periods per day for 5 days)
Number of subjects: 42
Study 18714203 — intervention group
Group type: COMPARATOR
Intervention: Standard nursery care without massage therapy
Number of subjects: 42
Study 16177615 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy warm-up (EWU)
Number of subjects: 8
Study 16177615 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard warm-up (HWU)
Number of subjects: 8
Study 16177615 — intervention group
Group type: COMPARATOR
Intervention: No warm-up (NWU)
Number of subjects: 8
Study 12529344 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy
Number of subjects: 448
Study 12529344 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 448
Study 10408495 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy with cyclophosphamide, methotrexate, and fluorouracil
Number of subjects: 0
Study 8911372 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine dermal patches postauricularly
Number of subjects: 20
Study 8911372 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 20
Study 1875230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (total dose, 20 g)
Number of subjects: 41
Study 1875230 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (total dose, 12 g) plus Amikacin (total dose, 5 g)
Number of subjects: 41
Study 6897369 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (FAC: fluorouracil, doxorubicin, and cyclophosphamide) with delays of less than 10 weeks
Number of subjects: 460
Study 6897369 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (FAC) with delays of 10-13 weeks
Number of subjects: 460
Study 6897369 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (FAC) with delays of 14-17 weeks
Number of subjects: 460
Study 6897369 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (FAC) with delays of greater than or equal to 18 weeks
Number of subjects: 460
Study 31328298 — intervention group
Group type: EXPERIMENTAL
Intervention: DX ICD system
Number of subjects: 150
Study 31328298 — intervention group
Group type: COMPARATOR
Intervention: Single-chamber ICD cohort
Number of subjects: 150
Study 31328298 — intervention group
Group type: COMPARATOR
Intervention: Dual-chamber ICD cohort
Number of subjects: 150
Study 29921393 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (cFNB) with 0.375% ropivacaine hydrochloride, 20 mL loading dose
Number of subjects: 46
Study 29921393 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA) with fentanyl, 0.05 mg loading dose
Number of subjects: 46
Study 27852324 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-hygiene intervention
Number of subjects: 775
Study 24025033 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy combined with functional strength training
Number of subjects: 288
Study 24025033 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy combined with movement performance therapy
Number of subjects: 288
Study 22595900 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 41
Study 22595900 — intervention group
Group type: COMPARATOR
Intervention: Healthy neonates
Number of subjects: 41
Study 22595900 — intervention group
Group type: COMPARATOR
Intervention: Nontreated neonates
Number of subjects: 41
Study 19641362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 19641362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily for 2 weeks
Number of subjects: 146
Study 17998017 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium supplementation (1000 microg Cr/d as Cr picolinate)
Number of subjects: 73
Study 17998017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 15251616 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 394
Study 15251616 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 394
Study 12226016 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (25 micro g, two puffs bid for 6 weeks)
Number of subjects: 27
Study 12226016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two puffs bid for 6 weeks)
Number of subjects: 27
Study 12226016 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol and Placebo
Number of subjects: 27
Study 9513753 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic hormone (ANH)
Number of subjects: 7
Study 9513753 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study 8122946 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lovastatin
Number of subjects: 431
Study 8122946 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg lovastatin
Number of subjects: 431
Study 8122946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 2518874 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg o.m.
Number of subjects: 0
Study 2518874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 792579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide‐methylprednisolone (group A)
Number of subjects: 13
Study 792579 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone‐procarbazine hydrochloride (group B)
Number of subjects: 13
Study 31548270 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of Hp0897 full-length protein
Number of subjects: 0
Study 31548270 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of Hp0897CTD
Number of subjects: 0
Study 31548270 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of Hp0897NTD
Number of subjects: 0
Study 31548270 — intervention group
Group type: EXPERIMENTAL
Intervention: Hp0897CTD
Number of subjects: 0
Study 31548270 — intervention group
Group type: EXPERIMENTAL
Intervention: Hp0897 full-length protein
Number of subjects: 0
Study 28033544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 5244
Study 28033544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5244
Study 25990624 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma galectin-3 (gal-3) levels in HD patients with left ventricular diastolic dysfunction (LVDD)
Number of subjects: 132
Study 25990624 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma galectin-3 (gal-3) levels in HD patients with normal diastolic function
Number of subjects: 132
Study 25990624 — intervention group
Group type: COMPARATOR
Intervention: Plasma galectin-3 (gal-3) levels in healthy controls
Number of subjects: 132
Study 25990624 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma gal-3 levels with E/E' ratio
Number of subjects: 132
Study 25990624 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma gal-3 levels with left atrial volume index
Number of subjects: 132
Study 25990624 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma gal-3 levels with E'
Number of subjects: 132
Study 25990624 — intervention group
Group type: EXPERIMENTAL
Intervention: Gal-3 cut-off point for diagnosis of LVDD
Number of subjects: 132
Study 23788809 — intervention group
Group type: EXPERIMENTAL
Intervention: High systolic blood pressure (HSBP) measurement
Number of subjects: 116
Study 23788809 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal systolic blood pressure (NSBP) measurement
Number of subjects: 116
Study 23788809 — intervention group
Group type: EXPERIMENTAL
Intervention: High diastolic blood pressure (HDBP) measurement
Number of subjects: 116
Study 23788809 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal diastolic blood pressure (NDBP) measurement
Number of subjects: 116
Study 21748770 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone alone (4 mg twice-daily)
Number of subjects: 137
Study 21748770 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone and metformin (4 mg rosiglitazone and 500 mg metformin twice-daily)
Number of subjects: 137
Study 21748770 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone and losartan (4 mg rosiglitazone and 50 mg losartan once-daily)
Number of subjects: 137
Study 19890172 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based educational and environmental intervention delivered by lay health educators
Number of subjects: 264
Study 16620334 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation uvulopalatoplasty with tonsillectomy (CP)
Number of subjects: 30
Study 16620334 — intervention group
Group type: COMPARATOR
Intervention: KTP laser-assisted uvulopalatoplasty without tonsillectomy (LAUP)
Number of subjects: 30
Study 14625121 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17beta‐E2 + NETA for 3 months
Number of subjects: 241
Study 14625121 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + MPA for 3 months
Number of subjects: 241
Study 14625121 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐E2 + MPA for 3 months
Number of subjects: 241
Study 14625121 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐E2 + MPA for 12 months
Number of subjects: 241
Study 14625121 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen levels in HRT users
Number of subjects: 241